Northwestern sues Moderna for patent infringement over 19 vaccines
By Blake Brittain
Oct 16 (Reuters) -Moderna MRNA.O was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax.
The lawsuit said Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.
A Moderna spokesperson said the company was aware of the lawsuit and will defend itself against the claims. Attorneys and spokespeople for Northwestern did not immediately respond to a request for comment.
The lawsuit adds to a web of U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their COVID vaccines, including one brought by Moderna against Pfizer in 2022. British pharmaceutical company GlaxoSmithKline sued Moderna in the same Delaware court on Tuesday for allegedly misusing GSK's LNP technology in its COVID-19 and RSV shots.
Evanston, Illinois-based Northwestern said its researchers pioneered the use of LNPs to deliver mRNA into human cells in 2009 and 2010. The university's lawsuit said the LNPs in Moderna's Spikevax work in the same way as its patented technology.
The school's complaint said Moderna could not have made its "rapid progress" in developing the vaccine "without appropriating the technological breakthroughs of prior researchers, including those at Northwestern."
Northwestern asked the court for an unspecified amount of monetary damages from Moderna's alleged infringement including royalties. Moderna earned $6.7 billion in revenue from Spikevax last year.
The case is Northwestern University v. Moderna Inc, U.S. District Court for the District of Delaware, No. 1:24-cv-01151.
For Northwestern: Rebecca Horwitz, John Hughes, Mac LeBuhn and Katherine Rhoades of Bartlit Beck
For Moderna: Not yet available
Read more:
Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine
GSK sues Moderna for US patent infringement over COVID, RSV vaccines
Reporting by Blake Brittain in Washington
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
